Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Experts meet on ESMO Congress to bring new hope to cancer patients

"A congress of records," is how Professor David J. Kerr, President of the European Society for Medical Oncology described the 35th ESMO Congress, at the opening press conference for the biggest medical oncology event in Europe. "We have had record numbers of submitted and accepted abstracts and are expecting a record number of attendees." The ESMO meeting brings together cancer specialists, patients, industry representatives and members of the media. The 35th ESMO Congress takes place at Fiera Milano City, in Milan, Italy, from 8 to 12 October 2010.

8 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H., professor of Urologic Surgery, will serve as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation study on prostate cancer.

8 Oct 2010

New imaging technique may help in early detection of prostate cancer

Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago.

8 Oct 2010

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens ultra-sensitive PSA assay.

7 Oct 2010

Should Medicare consider cost-effectiveness when setting reimbursement rates?

Medicare reimbursement rates should be based on how cost effective the treatment is for a particular illness, according to a piece by two policy experts in the October edition of Health Affairs.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Accuray announces 100,000th patient treated with CyberKnife Robotic Radiosurgery System

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that the 100,000th patient has been treated with the CyberKnife® Robotic Radiosurgery System, a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body. One in four patients treated with CyberKnife radiosurgery received treatment during Accuray's fiscal 2010, which ran July 2009 to June 2010.

6 Oct 2010

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Using novel technology allowing "virtual bone biopsies" researchers have found that a common treatment for prostate cancer called androgen deprivation therapy (ADT) is associated with structural decay of cortical and trabecular bone. The study has been accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer.

5 Oct 2010

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

4 Oct 2010

Cancer patients likely to experience memory impairment: Study

People with a history of cancer have a 40 percent greater likelihood of experiencing memory problems that interfere with daily functioning, compared with those who have not had cancer, according to results of a new, large study.

4 Oct 2010

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

4 Oct 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Experts meet on ESMO Congress to bring new hope to cancer patients

Abiraterone Phase III clinical data to be presented at ESMO meeting

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

New imaging technique may help in early detection of prostate cancer

Prostate cancer updates

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Cs-131 brachytherapy seed implant can treat metastasized cancer

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

Should Medicare consider cost-effectiveness when setting reimbursement rates?

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Accuray announces 100,000th patient treated with CyberKnife Robotic Radiosurgery System

Androgen deprivation therapy for prostate cancer associated with structural bone decay

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Amgen to present oncology portfolio results at ESMO Congress

Merck Serono to present Erbitux data at ESMO Congress

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Cancer patients likely to experience memory impairment: Study

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

What to know about prostate cancer eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Newsletters you may be interested in